BASF and Bota Biosciences have just brought a lab-designed, human-identical Collagen III fragment to market — and it is one of the clearest signals yet that AI-driven biomanufacturing is moving from trade-show demo to commercial cosmetic ingredient. Launched globally on June 30, 2026 under the name SkinNexus™ Collag3n, the active taps directly into the "collagen banking" trend that has been building across skincare for the past two years.

Key takeaways

  • What it is: a recombinant, vegan Collagen III fragment produced by yeast fermentation, engineered to a 100% human-identical amino-acid sequence.
  • How it was made: BASF and biotech partner Bota Biosciences screened over 2,000 candidate collagen fragments using Bota's "Physical AI" Saion platform before settling on this sequence.
  • Clinical signal: in 3D dermis models it lifted Collagen I by 48%, Collagen III by 82% and Collagen V by 71%; in a 4-week study on women aged 53–70 it improved sagging and wrinkle appearance, reportedly outperforming a benchmark collagen ingredient used at 10x the concentration.
  • Launch partner active: BASF released it alongside a companion precision peptide, NeoHelix™ Regenerate, aimed at the same collagen-renewal pathway.
  • Why it's trending: it is one of the first commercial cosmetic actives explicitly marketed as "AI-designed," and BASF is positioning it as a more cost-accessible alternative to premium collagen actives.

What SkinNexus Collag3n is

SkinNexus™ Collag3n is a recombinant Collagen III protein fragment, biofermented using engineered yeast rather than extracted from animal or marine sources — making it fully vegan. The headline claim is that its amino-acid sequence is 100% identical to human Collagen III, the collagen subtype most associated with skin elasticity and the "youthful" dermal matrix that thins with age.

The ingredient is the first commercial result of a collaboration between BASF's Care Chemicals business and Bota Biosciences, a biomanufacturing company whose Saion platform uses what it calls "Physical AI" — combining machine learning with automated wet-lab experimentation — to design and screen protein candidates faster than traditional discovery. BASF says the two companies screened more than 2,000 collagen fragment variants before identifying this sequence, running efficacy screening and industrial-scale feasibility in parallel rather than sequentially.

Benefits & suitable uses

Because it targets collagen homeostasis rather than acting as a single-mechanism ingredient, BASF's published data point to benefits across several layers of the aging cascade:

  • Collagen synthesis support: +48% Collagen I, +82% Collagen III and +71% Collagen V in 3D dermis-model testing — suggesting a broader remodeling effect than a Collagen-III-only ingredient might imply.
  • Visible anti-aging effects: improved sagging and reduced fine-line/wrinkle appearance after four weeks of use in a clinical study on women aged 53–70.
  • "Collagen banking" positioning: aimed at consumers using actives preventively, before visible collagen loss, rather than only as corrective treatment.

Product types where this class of recombinant collagen active typically fits: anti-aging serums and ampoules, night creams, eye contour treatments, and sheet-mask or booster formats built around a hero "collagen" claim.

Formulation considerations

BASF has not published a public technical data sheet with exact dosage and pH windows at the time of writing, so formulators should request the official Technical Data Sheet and safety documentation directly from BASF Care Chemicals before working with it. In general, recombinant collagen-fragment actives of this type are:

  • Water-soluble proteins best added to the aqueous phase in the cool-down step of a formulation, to avoid thermal denaturation of the protein structure.
  • Used at low, protein-typical dosing (commonly a fraction of a percent to a few percent, depending on the specific grade) — always confirm the supplier's recommended use level rather than assuming a category norm.
  • Sensitive to extreme pH and strong oxidizers/preservative systems, so compatibility and stability screening in the target base is essential, as it is with any protein or peptide active.
  • Marketing-claim relevant: because the "human-identical" and "AI-designed" story is central to this ingredient's appeal, brands will want INCI transparency and support from BASF on substantiating any collagen-related claims used on pack.

Why it matters for brands & formulators

Three things make this launch worth watching beyond the ingredient itself. First, it is a visible example of a major supplier explicitly branding an active around "AI-driven discovery" — a positioning story brands can borrow for their own marketing. Second, BASF is pitching it as a cost-competitive, "democratized" alternative in a collagen-active market that has skewed premium, which could open collagen-banking claims to a wider range of price tiers. Third, it arrives paired with a companion peptide (NeoHelix Regenerate) rather than as a standalone SKU, suggesting BASF sees this as the start of a platform rather than a one-off launch — worth tracking for brands building a multi-step anti-aging routine around a single supplier's actives.

BASF and Bota Biosciences official press release announcing SkinNexus Collag3n
BASF and Bota Biosciences' official joint announcement of SkinNexus™ Collag3n, June 30, 2026. Photo/screenshot credit: basf.com.

FAQ

Is SkinNexus Collag3n vegan?

Yes. It is produced by yeast fermentation (biotechnology), not extracted from animal or marine collagen sources.

How is it different from marine or bovine collagen peptides?

Traditional collagen peptides are hydrolyzed from animal or marine sources and vary in sequence. SkinNexus Collag3n is a recombinant fragment engineered to match the human Collagen III sequence directly, which BASF frames as a more targeted, biomimetic approach.

Is it available for brands to formulate with now?

BASF and Bota Biosciences announced the commercial market launch on June 30, 2026, following its debut at in-cosmetics Global in April 2026. Brands and formulators should contact BASF Care Chemicals directly for samples, technical data sheets and regulatory documentation.

This article is an independent market-insight summary based on public statements from BASF, Bota Biosciences and cosmetics-industry trade press. It is not sponsored by, or published on behalf of, BASF or Bota Biosciences. Formulators should always confirm current specifications, use levels and regulatory status directly with the supplier before use.